News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/thrombocytopenia_ErhaborOsaro-230.jpg)
FDA approves drug for thrombocytopenia in CLD
- Author:
- HT Staff
The US Food and Drug Administration (FDA) has approved avatrombopag (DOPTELET®), a second-generation thrombopoietin receptor agonist....
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/AML_cells_Credit_Lance_Liotta_230.jpg)
Protein may be therapeutic target for AML
- Author:
- HT Staff
A signaling protein may be a “potent” therapeutic target for acute myeloid leukemia (AML), according to a paper published in the Journal of...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/imbruvica-janssen_220.jpg)
Older, cheaper drug formulation to remain available
- Author:
- HT Staff
The 140 mg capsules of Imbruvica® (ibrutinib) will remain on the market, according to Pharmacyclics LLC. Pharmacyclics (an AbbVie company) and...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/prescriptions_Credit_Steven_Harbour_230-1.jpg)
Drug makers may be blocking generic competition
- Author:
- HT Staff
The US Food and Drug Administration (FDA) has released a list of companies that “may be pursuing gaming tactics to delay generic competition.”...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/blood_bags_Credit_Elise_Amendola_230.jpg)
Better matching for blood transfusions
- Author:
- HT Staff
Researchers have developed software that could enable more precise matching for blood transfusions, according to a paper published in The Lancet...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/lab_mouse_closeup_240.jpg)
Bacterial signals set the stage for PMP
- Author:
- HT Staff
Preclinical research suggests bacterial signals are crucial to the development of pre-leukemic myeloproliferation (PMP). Researchers found that...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/scientist_using_a_computer_Credit_Darren_Baker_230.jpg)
EHRs enhance clinical trial follow-up
- Author:
- HT Staff
Electronic health records (EHRs) can enhance results from randomized controlled trials (RCTs), according to research published in Scientific...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/vials_drugs_Bill_Branson_230.jpg)
Regimen can improve DFS in newly diagnosed T-ALL
- Author:
- HT Staff
The addition of nelarabine can improve treatment outcomes for certain patients with T-cell acute lymphoblastic leukemia (T-ALL), according to a...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/sleeping-woman-Petr-Kratochvil-220.jpg)
Treating insomnia in cancer survivors
- Author:
- HT Staff
Treatment with acupuncture or cognitive behavioral therapy (CBT) can decrease the severity of insomnia among cancer survivors, according to new...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/red_blood_cells_eurekalert-240.jpg)
FDA approves first epoetin alfa biosimilar
- Author:
- HT Staff
The US Food and Drug Administration (FDA) has approved epoetin alfa-epbx (Retacrit), a biosimilar to epoetin alfa (Epogen/Procrit). Epoetin alfa-...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/anopheles_albimanus_mosquito_Credit_James_Gathany_230.jpg)
Team analyzes skin odor to detect malaria
- Author:
- HT Staff
Changes in skin odor can reveal malaria infection in patients with no external symptoms, according to research published in PNAS. Researchers...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/CLL_cells.jpg)
Umbralisib has ‘distinct’ safety profile
- Author:
- HT Staff
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/blood_for_transfusion_Credit_UAB_Hospital_230.jpg)
FDA approves new use for Zika test
- Author:
- HT Staff
The US Food and Drug Administration (FDA) has approved an additional use for the cobas Zika test. The approval allows for the streamlined...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/researchers_woman_micro_man_standing_Rhoda_Baer_230.jpg)
Study reveals gender imbalance in cancer research funding
- Author:
- HT Staff
A new study suggests male investigators in the UK receive more funding for cancer research than their female counterparts. Researchers analyzed...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/patient_receives_chemo_older_woman_Credit_Rhoda_Baer_220.jpg)
NCCN releases guidelines for AML patients
- Author:
- HT Staff
The National Comprehensive Cancer Network (NCCN) has released guidelines for patients with acute myeloid leukemia (AML). The guidelines are...